Search

Search Results

• 

  Methotrexate in the therapeutic pathway of patients with psoriasis. Analysis of clinical practice data and comparison with guidelines

  Valeria Corazza, Francesco Cusano, Ornella De Pità, Luigi Rossi, G. Giovanni Virno

  28-12-2021

  https://doi.org/10.4081/dr.2022.9454

  4149

  PDF: 692

  APPENDIX: 197

  HTML: 20
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1167

  PDF: 575

  HTML: 27

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2856

  PDF: 1014

  HTML: 39

• Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

  Fawaz Aljehani, Shumukh Alqahtani, Sara Alharbi, Seham Alsulami

  06-12-2024

  https://doi.org/10.4081/dr.2024.10171

  1848

  PDF: 489

  HTML: 56

• Hidradenitis suppurativa: state-of-the-art review and update

  Marco Virone, Elena Zappia, Alberto Di Caro, Davide Carlesimo, Nicoletta Bernardini, Giovanni Pellacani, Antonio Giovanni Richetta, Steven Paul Nisticò, Annunziata Dattola

  27-08-2025

  https://doi.org/10.4081/dr.2025.10328

  1308

  PDF: 837

  HTML: 17
• 

  Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus

  Martina Burlando, Elena Campione, Aldo Cuccia, Giovanna Malara, Luigi Naldi, Francesca Prignano, Leonardo Zichichi

  29-12-2022

  https://doi.org/10.4081/dr.2023.9613

  1826

  PDF: 564

  HTML: 102

• Treatment satisfaction among patients with psoriasis in Saudi Arabia

  Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi

  15-04-2024

  https://doi.org/10.4081/dr.2024.9967

  1125

  PDF: 645

  HTML: 51

• Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

  Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

  01-07-2025

  https://doi.org/10.4081/dr.2025.10315

  629

  PDF: 323

  HTML: 25
• 

  Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

  Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly

  21-11-2022

  https://doi.org/10.4081/dr.2022.9265

  1578

  PDF: 473

  HTML: 37
• 

  Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

  Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

  25-06-2020

  https://doi.org/10.4081/dr.2020.8642

  1420

  PDF: 775

  HTML: 19
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1224

  PDF: 864

  HTML: 49

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  1085

  PDF: 573

  SUPPLEMENTARY MATERIAL: 187

  HTML: 23
• 

  Erythrodermic psoriasis treated with apremilast

  John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

  19-09-2016

  https://doi.org/10.4081/dr.2016.6599

  2216

  PDF: 991

  HTML: 613

• Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

  Paolo Dapavo, Matteo Megna, Marina Talamonti

  09-08-2024

  https://doi.org/10.4081/dr.2024.9999

  1842

  PDF: 740

  HTML: 109

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  509

  PDF: 325

  HTML: 25

• Natural language processing of online support group postings reveals patients’ perspectives on strategies for managing psoriasis

  Karan Rajalingam, Phillip M. Johansen, Nicole J. Levin, Jerry Qi, Oge Marques

  11-09-2023

  https://doi.org/10.4081/dr.2023.9824

  1004

  PDF: 973

  HTML: 40
• 

  Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

  Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi

  01-10-2018

  https://doi.org/10.4081/dr.2018.7859

  2114

  PDF: 1090

  HTML: 86

• Acute generalized exanthematous pustulosis triggered by dupilumab

  Caterina Mariarosaria Giorgio, Gaetano Licata, Giuseppe Argenziano, Vittorio Tancredi, Anna Balato, Eugenia Veronica Di Brizzi

  23-07-2025

  https://doi.org/10.4081/dr.2025.10219

  538

  PDF: 356

  HTML: 28
• 

  Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

  Vasiliki Tasouli-Drakou, May Nguyen, Hannah Guinn, Omron Hassan, Sneha Butala, Sheshanna Phan

  21-11-2022

  https://doi.org/10.4081/dr.2022.9492

  1825

  PDF: 701

  HTML: 91

• Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

  Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo

  30-05-2025

  https://doi.org/10.4081/dr.2025.10414

  882

  PDF: 469

  HTML: 52
• 

  Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

  Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

  14-03-2022

  https://doi.org/10.4081/dr.2022.9091

  2666

  PDF: 657

  HTML: 16
• 

  Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

  Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza

  21-11-2022

  https://doi.org/10.4081/dr.2022.9447

  1426

  PDF: 431

  HTML: 53

• Anisakis simplex and urticaria. What we know about its real incidence and management in dermatological settings?

  Sanja Javor, Donatella Bignardi, Matteo Borro, Cesare Massone

  29-08-2023

  https://doi.org/10.4081/dr.2023.9819

  1277

  PDF: 726

  HTML: 29

• Psoriasiform eruption induced by dupilumab successfully treated with upadacitinib

  Mattia Minghini, Natale Schettini, Lucrezia Pacetti, Chiara Bocchi, Alessandro Borghi

  16-10-2025

  https://doi.org/10.4081/dr.2025.10588

  413

  PDF: 215

  HTML: 3

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  572

  PDF: 390

  HTML: 14